Sort
82,697 grants matching “vaccine development”
HIV-1 Env Trimer Crystallography
$765,246Ian A Wilson · Progenics Pharmaceuticals, Inc. · P01 · FY2010 · AI
Western New England Maternal Pediatric Adolescent AIDS Clinical Trials Unit
$765,163Katherine F Luzuriaga · Univ Of Massachusetts Med Sch Worcester · U01 · FY2010 · AI
An infrastructure for cancer virus discovery from next-generation sequencing data
$765,137Matthew L Meyerson · Dana-Farber Cancer Inst · RC2 · FY2009 · CA
PERSISTENCE OF IMMUNE RESPONSES TO THE RECOMBINANT ZOSTER VACCINE IN IMMUNE COMPROMISED HOSTS WITH END-STAGE RENAL DISEASE WITH AND WITHOUT KIDNEY TRANSPLANTATION
$765,085Adriana Weinberg · University Of Colorado Denver · U01 · FY2025 · AI
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
$765,082Yuan Liu · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · AI
Dissecting the pathogenesis of HIV-TB Immune reconstitution inflammatory syndrome
$765,082Philana Ling Lin · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AI
Development of a vaccine for Ebola virus in plant system
$765,070Charles Joel Arntzen · Arizona State University-Tempe Campus · U01 · FY2006 · AI
Mechanisms of compromised CD8 T cell responses to vaccination in malaria experienced hosts
$765,058John T. Harty · University Of Iowa · R01 · FY2024 · AI
Cell-specific nanocarrier with endocytic and endosomolytic activities for therapeutic genome editing
$765,041Kit S Lam · University Of California At Davis · UG3 · FY2020 · TR
Elucidation of Assembly and Budding Mechanisms of SARS-CoV-2
$765,004Robert Virgil Stahelin · Purdue University · R01 · FY2024 · AI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2019 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2021 · CA
Core Center for Translational Addiction Sciences
$765,000Kathryn A. Cunningham · University Of Texas Med Br Galveston · P30 · FY2010 · DA
Core Center for Translational Addiction Sciences
$765,000Kathryn A. Cunningham · University Of Texas Med Br Galveston · P30 · FY2009 · DA
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$765,000Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2011 · AI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2020 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2022 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2018 · CA
Oral immunization against HIV/AIDS with prime-boost strategies
$764,999Shiu-Lok Hu · University Of Washington · R01 · FY2014 · DE
Assessing ADCC and Fc-mediated Protection against HIV
$764,967David T Evans · University Of Wisconsin-Madison · R01 · FY2021 · AI
TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCERIDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS
$764,880Chinthalapally V. Rao · University Of Oklahoma Hlth Sciences Ctr · N01 · FY2024 · CA
Identification of novel immunogenic proteins from Bordetella pertussis
$764,867Purnima Dubey · Ohio State University · R01 · FY2022 · AI
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
$764,846Mihai Luchian Azoitei · Duke University · R01 · FY2024 · AI
Papillomavirus Virion Proteins and Vaccines
$764,819Douglas R. Lowy · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Mechanisms of protection against shigellosis in children
$764,815Marcela F Pasetti · University Of Maryland Baltimore · R01 · FY2023 · AI